NPC Clinical Trials

45 recruitingLast updated: June 18, 2026

There are 45 actively recruiting npc clinical trials across 9 countries. Studies span Phase 3, Phase 2, Phase 1, Not Applicable. Top locations include Guangzhou, Guangdong, China, Changsha, Hunan, China, Nanning, Guangxi, China. Updated daily from ClinicalTrials.gov.


NPC Trials at a Glance

45 actively recruiting trials for npc are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 3 with 17 trials, with the heaviest enrollment activity in Guangzhou, Changsha, and Nanning. Lead sponsors running npc studies include Sun Yat-sen University, Ming-Yuan Chen, and Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Browse npc trials by phase

Treatments under study

About NPC Clinical Trials

Looking for clinical trials for NPC? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new NPC trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about NPC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 45 trials

Recruiting
Phase 1

Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors

Head & Neck CancerNasopharyngeal Cancinoma (NPC)
West China Hospital9 enrolled1 locationNCT07625423
Recruiting
Phase 3

RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma (NPC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences651 enrolled1 locationNCT07590024
Recruiting

Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC

Nasopharyngeal Carcinoma (NPC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences900 enrolled1 locationNCT07618078
Recruiting
Phase 1Phase 2

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Squamous Cell CarcinomaAdvanced or Metastatic Squamous Non-Small Cell Lung CancerAdvanced Head and Neck Squamous Cell Carcinoma+4 more
Hummingbird Bioscience398 enrolled20 locationsNCT05910827
Recruiting
Phase 2

LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC

Nasopharangeal CancerNasopharyngeal Cancinoma (NPC)
Sun Yat-sen University55 enrolled2 locationsNCT07325539
Recruiting
Phase 3

Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid

Nasopharyngeal Cancinoma (NPC)Radiation-induced Oral Mucositis
Sun Yat-sen University386 enrolled16 locationsNCT07311772
Recruiting
Phase 1Phase 2

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Nasopharyngeal Cancinoma (NPC)Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharynx Carcinoma
Sun Yat-sen University148 enrolled1 locationNCT06802835
Recruiting

International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer

Nasopharyngeal Cancinoma (NPC)
The University of Hong Kong-Shenzhen Hospital5,000 enrolled1 locationNCT07013461
Recruiting

Lynch Syndrome X-Talk of Enteral Mucosa With Immune System

Hereditary Cancer SyndromeHereditary CancerLynch Syndrome+19 more
San Raffaele University300 enrolled5 locationsNCT06708429
Recruiting
Phase 2

Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy

Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University59 enrolled1 locationNCT07496190
Recruiting
Phase 3

Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.

Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University700 enrolled6 locationsNCT07201337
Recruiting
Phase 2

LDRT and Chemoimmunotherapy in NPC With Liver Metastasis

Nasopharyngeal Cancinoma (NPC)
Hunan Cancer Hospital26 enrolled7 locationsNCT06788002
Recruiting
Phase 2

Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University243 enrolled4 locationsNCT07362979
Recruiting
Phase 3

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Nasopharyngeal Carcinoma (NPC)
First Affiliated Hospital of Guangxi Medical University266 enrolled1 locationNCT07459296
Recruiting
Phase 3

Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma (NPC)
Affiliated Hospital of Guangdong Medical University180 enrolled1 locationNCT07327216
Recruiting

IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features

Nasopharyngeal Cancinoma (NPC)Intensity Modulated RadiotherapyStage IB
Qiaojuan Guo169 enrolled1 locationNCT07376603
Recruiting
Phase 2

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial

Nasopharyngeal Carcinoma (NPC)First-line Treatment Failure Nasopharyngeal Carcinoma
Sun Yat-sen University41 enrolled1 locationNCT07101744
Recruiting
Phase 3

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

Nasopharyngeal Carcinoma (NPC)
Man Hu300 enrolled1 locationNCT07340515
Recruiting
Phase 3

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

Nasopharyngeal Carcinoma (NPC)
Ming-Yuan Chen456 enrolled12 locationsNCT07328841
Recruiting
Phase 3

Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC

Nasopharyngeal Carcinoma (NPC)
Fudan University462 enrolled6 locationsNCT07303023